NZ578065A - Methods for treating psoriasis with an antibody which binds to an epitope - Google Patents

Methods for treating psoriasis with an antibody which binds to an epitope

Info

Publication number
NZ578065A
NZ578065A NZ578065A NZ57806508A NZ578065A NZ 578065 A NZ578065 A NZ 578065A NZ 578065 A NZ578065 A NZ 578065A NZ 57806508 A NZ57806508 A NZ 57806508A NZ 578065 A NZ578065 A NZ 578065A
Authority
NZ
New Zealand
Prior art keywords
antibody
epitope
binds
methods
treating psoriasis
Prior art date
Application number
NZ578065A
Other languages
English (en)
Inventor
Joaquin Mario Valdes
Elliot Keith Chartash
William T Barchuk
Susan K Paulson
Alexandra B Kimball
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ578065A publication Critical patent/NZ578065A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ578065A 2007-01-16 2008-01-16 Methods for treating psoriasis with an antibody which binds to an epitope NZ578065A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US88076707P 2007-01-16 2007-01-16
US90402207P 2007-02-27 2007-02-27
US92596007P 2007-04-24 2007-04-24
US96176407P 2007-07-24 2007-07-24
US99701207P 2007-09-28 2007-09-28
PCT/US2008/000564 WO2008088823A2 (en) 2007-01-16 2008-01-16 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
NZ578065A true NZ578065A (en) 2012-09-28

Family

ID=39636572

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ578065A NZ578065A (en) 2007-01-16 2008-01-16 Methods for treating psoriasis with an antibody which binds to an epitope

Country Status (15)

Country Link
US (2) US7776331B1 (enExample)
EP (2) EP2839743A1 (enExample)
JP (2) JP2010515774A (enExample)
KR (2) KR20150038227A (enExample)
CN (1) CN104524567A (enExample)
AU (1) AU2008205512B2 (enExample)
BR (1) BRPI0806605A2 (enExample)
CA (1) CA2675233A1 (enExample)
HK (1) HK1203305A1 (enExample)
IL (1) IL199739A0 (enExample)
MX (1) MX2009007570A (enExample)
NZ (1) NZ578065A (enExample)
RU (2) RU2475265C2 (enExample)
SG (1) SG177982A1 (enExample)
WO (1) WO2008088823A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7776331B1 (en) * 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
EP2527364A1 (en) * 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
NZ602511A (en) 2008-03-18 2014-03-28 Abbvie Inc Methods for treating psoriasis
US20120225080A1 (en) * 2008-03-18 2012-09-06 Abbott Laboratories Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor
US8563697B2 (en) * 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
CN102202655B (zh) * 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US11643460B2 (en) * 2014-10-28 2023-05-09 Staley Brod Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease
RU2562316C1 (ru) * 2014-12-10 2015-09-10 Сергей Владимирович Москвин Способ лазерной терапии больных псориазом

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DK0614984T4 (da) * 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
EP0794726A4 (en) * 1994-10-20 1998-01-07 Instent Inc CYTOSCOPIC SYSTEM FOR IMPLANTATION OF AN EXTENDER
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
AU7257696A (en) 1996-10-11 1998-05-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
EP0936923B1 (en) 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
WO1999009055A2 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
ATE274920T1 (de) 1997-10-31 2004-09-15 Wyeth Corp Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
DK1818343T3 (da) * 1998-01-23 2012-07-16 Hoffmann La Roche Antistoffer mod humant IL-12
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
JP3579355B2 (ja) 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU3921600A (en) * 1999-03-25 2000-10-09 Abbott Gmbh & Co. Kg Human antibodies that bind human il-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US8080247B2 (en) 2000-08-07 2011-12-20 Janssen Biotech, Inc. Anti-IL-12 antibodies
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
JP2006502116A (ja) * 2002-07-12 2006-01-19 メダレックス， インク． タンパク質の酸化分解を防ぐ方法及び組成物
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
PT1698640E (pt) * 2003-10-01 2016-03-31 Kyowa Hakko Kirin Co Ltd Processo para estabilizar um anticorpo e composição sob a forma de solução estabilizada contendo o anticorpo
EP1694317A4 (en) * 2003-12-19 2010-05-12 Protemix Corp Ltd COPPER ANTAGONIST COMPOUNDS
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
EP1713502A1 (de) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
RU2292215C2 (ru) 2004-05-21 2007-01-27 Дмитрий Васильевич Николенко Комплекс для лечения псориаза и способ лечения
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CN101048427B (zh) 2004-07-23 2015-01-14 健泰科生物技术公司 抗体或其片段的结晶
PT1896073E (pt) * 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
WO2008033239A2 (en) * 2006-09-11 2008-03-20 Applera Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
WO2008046033A2 (en) 2006-10-13 2008-04-17 Centocor Ortho Biotech Inc. Enhancement of hybridoma fusion efficiencies through cell synchronization
US7776331B1 (en) * 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
EP2527364A1 (en) * 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
NZ602511A (en) * 2008-03-18 2014-03-28 Abbvie Inc Methods for treating psoriasis
US20120225080A1 (en) 2008-03-18 2012-09-06 Abbott Laboratories Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
EP2661448A4 (en) * 2011-01-07 2015-09-16 Abbvie Inc ANTI-IL-12 / IL-23 ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
US9051368B2 (en) 2015-06-09
US7776331B1 (en) 2010-08-17
KR20150038227A (ko) 2015-04-08
JP2015145389A (ja) 2015-08-13
WO2008088823A2 (en) 2008-07-24
US20100297143A1 (en) 2010-11-25
AU2008205512A1 (en) 2008-07-24
RU2012147583A (ru) 2014-05-20
KR20090100461A (ko) 2009-09-23
JP2010515774A (ja) 2010-05-13
EP2839743A1 (en) 2015-02-25
EP2117303A4 (en) 2011-06-08
WO2008088823A3 (en) 2008-11-20
IL199739A0 (en) 2010-04-15
HK1203305A1 (en) 2015-10-30
EP2117303A2 (en) 2009-11-18
RU2475265C2 (ru) 2013-02-20
CN104524567A (zh) 2015-04-22
MX2009007570A (es) 2009-07-22
RU2009131080A (ru) 2011-02-27
AU2008205512B2 (en) 2014-06-12
SG177982A1 (en) 2012-02-28
CA2675233A1 (en) 2008-07-24
BRPI0806605A2 (pt) 2011-09-06

Similar Documents

Publication Publication Date Title
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
NZ598722A (en) Methods for treating psoriasis
NZ587765A (en) Methods for treating psoriasis
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
NZ592786A (en) Methods and compositions for treating complement-associated disorders using eculizumab
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
NZ606095A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
NZ603883A (en) Method for preparing antibodies having improved properties
SI1734995T1 (sl) Monoklonska protitelesa proti hepatocitnemu rastnemu faktorju
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
WO2008076257A3 (en) Treating cancer with anti-igflr antibody 19d12 = sch 717454
WO2008152822A1 (ja) 医薬
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
WO2008108910A3 (en) Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
WO2009017161A1 (ja) 炎症性サイトカインの抑制剤
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ABBOTT LABORATORIES, US

Free format text: OLD OWNER(S): ABBOTT LABORATORIES; JOAQUIN MARIO VALDES; ELLIOT KEITH CHARTASH; WILLIAM T BARCHUK; SUSAN K PAULSON; ALEXANDRA B KIMBALL

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO APPLICATION (71)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 JAN 2015 BY AJ PARK

Effective date: 20130424

ASS Change of ownership

Owner name: ABBVIE INC., US

Effective date: 20140327

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JAN 2016 BY THOMSON REUTERS

Effective date: 20141221

LAPS Patent lapsed